The idiopathic inflammatory myopathy (IIM) landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians …
Although advances in antiretroviral therapy (ART) have transformed human immunodeficiency virus (HIV) into a manageable chronic condition, important gaps persist in the consistent, equitable application of care across diverse populations and global settings. Rapid innovation—including long-acting injectable (LAI) and multi-mechanism …
Despite significant advances in human immunodeficiency virus (HIV) care, there are persistent gaps in translating clinical trial evidence into real-world practice, limiting optimal outcomes. Clinicians must keep pace with a rapidly evolving treatment landscape—including antiretroviral therapy (ART) such as long-acting …
While treatment innovations have significantly improved outcomes for individuals with human immunodeficiency virus (HIV), gaps persist in the consistent delivery of equitable, guideline-concordant care, particularly among diverse and underserved populations. Optimal use of therapies, including long-acting injectables (LAIs), is restricted …
Despite major advances in human immunodeficiency virus (HIV) management—including effective antiretroviral therapy (ART) and long-acting injectables—gaps in screening, testing, and diagnosis continue to limit patient outcomes and prevention efforts. Many clinicians, particularly in primary care and community settings, face challenges …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …
Despite advances in generalized myasthenia gravis (gMG), muscle-specific tyrosine kinase (MuSK+), low density lipoprotein receptor related protein 4 (LRP4+), and triple-seronegative MG remain underrecognized and are often managed using paradigms derived from acetylcholine receptor (AChR)-positive disease. Neurologists, neuromuscular specialists, nurse …